MX2017009164A - Moduladores de canales de ca2+ activados de liberacion de ca2+ (crac) y usos farmaceuticos de los mismos. - Google Patents

Moduladores de canales de ca2+ activados de liberacion de ca2+ (crac) y usos farmaceuticos de los mismos.

Info

Publication number
MX2017009164A
MX2017009164A MX2017009164A MX2017009164A MX2017009164A MX 2017009164 A MX2017009164 A MX 2017009164A MX 2017009164 A MX2017009164 A MX 2017009164A MX 2017009164 A MX2017009164 A MX 2017009164A MX 2017009164 A MX2017009164 A MX 2017009164A
Authority
MX
Mexico
Prior art keywords
crac
modulators
release
same
pharmaceutical uses
Prior art date
Application number
MX2017009164A
Other languages
English (en)
Other versions
MX379440B (es
Inventor
l greenberg Milton
T Ransom John
a white Clayton
S Muzaffery Omed
c newman Andrew
Original Assignee
Vivreon Biosciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivreon Biosciences Llc filed Critical Vivreon Biosciences Llc
Publication of MX2017009164A publication Critical patent/MX2017009164A/es
Publication of MX379440B publication Critical patent/MX379440B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen en la presente compuestos que modulan la actividad de canales de CRAC, métodos para hacer tales compuestos, composiciones farmacéuticas y medicamentos que contienen tales compuestos y métodos para usar tales compuestos en el tratamiento de condiciones, enfermedades o trastornos asociados con actividad de canales de CRAC. (ver Dibujo).
MX2017009164A 2015-01-13 2016-01-11 Moduladores de canales de ca2+ activados de liberación de ca2+ (crac) y usos farmacéuticos de los mismos. MX379440B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562103033P 2015-01-13 2015-01-13
PCT/US2016/012909 WO2016115054A2 (en) 2015-01-13 2016-01-11 Modulators of ca2+ release-activated ca2+ (crac) channels and pharmaceutical uses thereof

Publications (2)

Publication Number Publication Date
MX2017009164A true MX2017009164A (es) 2018-03-06
MX379440B MX379440B (es) 2025-03-11

Family

ID=56406559

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009164A MX379440B (es) 2015-01-13 2016-01-11 Moduladores de canales de ca2+ activados de liberación de ca2+ (crac) y usos farmacéuticos de los mismos.

Country Status (9)

Country Link
US (1) US10213412B2 (es)
EP (1) EP3245189B1 (es)
JP (1) JP6764866B2 (es)
CN (1) CN107207431B (es)
AU (1) AU2016207014B2 (es)
CA (1) CA2969814C (es)
ES (1) ES2825798T3 (es)
MX (1) MX379440B (es)
WO (1) WO2016115054A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107207431B (zh) 2015-01-13 2021-02-09 维夫雷昂生物科学有限责任公司 Ca2+释放激活的Ca2+(CRAC)通道的调节剂及其药物用途
AU2018353533A1 (en) * 2017-10-17 2020-05-28 Rhizen Pharmaceuticals Sa CRAC channel modulators for treating esophageal cancer
JP2021501160A (ja) * 2017-10-30 2021-01-14 ルヒゼン ファーマスティカルズ エスエー 血液がんおよび固形がんの処置のためのカルシウム放出活性化カルシウムチャネルモジュレーター
WO2020053834A1 (en) 2018-09-14 2020-03-19 Rhizen Pharmaceuticals Sa Compositions comprising a crac inhibitor and a corticosteroid and methods of use thereof
KR20220154165A (ko) * 2020-03-16 2022-11-21 조마젠 바이오사이언시즈 엘티디 Nlrp3 조절제
CN116261468A (zh) * 2020-05-20 2023-06-13 钙医学公司 治疗急性肾损伤的方法和组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4644009A (en) * 1984-10-29 1987-02-17 Usv Pharmaceutical Corporation Aryl-alkyl heterocyclic compounds
US5041442A (en) * 1990-07-31 1991-08-20 Syntex (U.S.A.) Inc. Pyrrolo(1,2-a)pyrazines as inhibitors of gastric acid secretion
WO1993017671A1 (en) * 1992-03-06 1993-09-16 Statens Seruminstitut Treatment and prophylaxis of diseases caused by parasites, or bacteria
ATE229020T1 (de) * 1994-01-19 2002-12-15 Sankyo Co Pyrrolopyridazin-derivate
JP3143571B2 (ja) * 1994-01-19 2001-03-07 三共株式会社 ピロロピリダジン誘導体
JP2000256358A (ja) * 1999-03-10 2000-09-19 Yamanouchi Pharmaceut Co Ltd ピラゾール誘導体
KR20070057965A (ko) * 2004-09-21 2007-06-07 신타 파마슈티칼스 코프. 염증 및 면역 관련 용도를 위한 화합물
US7951794B2 (en) * 2005-06-24 2011-05-31 Actelion Pharmaceuticals Ltd. Thiophene derivatives
US8993612B2 (en) * 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
US8377970B2 (en) * 2009-10-08 2013-02-19 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
TW201130488A (en) * 2010-02-03 2011-09-16 Daiichi Sankyo Co Ltd Pyrrole compound
PT2723710T (pt) * 2011-06-27 2016-11-14 Newron Pharm Spa Derivados fluorados de arilalquilaminocarboxamida
AU2014282886A1 (en) * 2013-06-17 2015-12-17 Lupin Limited Pyrrole derivatives as alpha 7 nAChR modulators
CN107207431B (zh) 2015-01-13 2021-02-09 维夫雷昂生物科学有限责任公司 Ca2+释放激活的Ca2+(CRAC)通道的调节剂及其药物用途

Also Published As

Publication number Publication date
EP3245189A2 (en) 2017-11-22
EP3245189B1 (en) 2020-07-22
JP2018502083A (ja) 2018-01-25
MX379440B (es) 2025-03-11
CN107207431A (zh) 2017-09-26
AU2016207014A1 (en) 2017-07-06
CA2969814C (en) 2023-06-13
EP3245189A4 (en) 2018-07-18
US10213412B2 (en) 2019-02-26
ES2825798T3 (es) 2021-05-17
CN107207431B (zh) 2021-02-09
JP6764866B2 (ja) 2020-10-07
WO2016115054A2 (en) 2016-07-21
HK1245797A1 (en) 2018-08-31
CA2969814A1 (en) 2016-07-21
US20180263960A1 (en) 2018-09-20
AU2016207014B2 (en) 2020-07-16
WO2016115054A3 (en) 2016-09-01

Similar Documents

Publication Publication Date Title
CL2018003142A1 (es) Moduladores de la vía de estrés integrada
CL2018003265A1 (es) Modulares del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
MX2018016273A (es) Compuestos heterociclicos como inmunomoduladores.
MX2020001360A (es) Macrociclos de diarilo como moduladores de la proteina quinasa.
CL2017001046A1 (es) Inhibidoes del bromodominio
MX2018003388A (es) Agonistas del receptor farnesoide x y usos de los mismos.
NI201600164A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
MX2016004340A (es) Compuestos heterociclicos y usos de los mismos.
MX390120B (es) Moduladores de la somatostatina y usos de los mismos.
MX2013012896A (es) Compuestos novedosos como moduladores de proteina cinasas.
ECSP19034535A (es) Inhibidores de la magl
CO2018013077A2 (es) Inhibidores de la arginasa y sus aplicaciones terapéuticas
CL2016003212A1 (es) Derivados de indolín-2-ona o pirrolo-piridín-2-ona.
ECSP16078782A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
MX2017009164A (es) Moduladores de canales de ca2+ activados de liberacion de ca2+ (crac) y usos farmaceuticos de los mismos.
MX2017014375A (es) Moduladores del ccr2.
ECSP18049420A (es) Composiciones novedosas, usos y métodos para hacerlas
MX2016014773A (es) Vectores de virus adenoasociados para el tratamiento de trastornos de almacenamiento lisosomico.
CO6551721A2 (es) Moduladores de cinasa novedosos
MX375706B (es) Compuestos de inhibidor de autotaxina.
BR112016006994A2 (pt) inibidores de erk e métodos de uso
CL2019002583A1 (es) Inhibidores duales de magl y faah.
MX2019000946A (es) Administracion y dosificacion de diaminofenotiazinas.
CL2015002222A1 (es) Compuestos de azabencimidazol como inhibidores de isoenzimas pde4 para el tratamiento del snc y otros trastornos.
DOP2017000087A (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y métodos de uso de los mismos